{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:24:13Z","timestamp":1786951453567,"version":"build-2736575974"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100018864","name":"Otsuka Canada Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021138","name":"Lundbeck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021138","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40263-026-01315-7","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:48:08Z","timestamp":1785242888000},"page":"1185-1206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-7272","authenticated-orcid":false,"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6403-0861","authenticated-orcid":false,"given":"Michael E.","family":"Thase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-4333","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Therrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Marilise","family":"Marrache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Ikehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Ardic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4066-0009","authenticated-orcid":false,"given":"Matthieu","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"1315_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-981-32-9705-0_14","volume":"1191","author":"KW Choi","year":"2020","unstructured":"Choi KW, Kim YK, Jeon HJ. Comorbid anxiety and depression: clinical and conceptual consideration and transdiagnostic treatment. Adv Exp Med Biol. 2020;1191:219\u201335. https:\/\/doi.org\/10.1007\/978-981-32-9705-0_14.","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"1315_CR2","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1017\/s0033291704002612","volume":"34","author":"M Fava","year":"2004","unstructured":"Fava M, Alpert JE, Carmin CN, Wisniewski SR, Trivedi MH, Biggs MM, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34(7):1299\u2013308. https:\/\/doi.org\/10.1017\/s0033291704002612.","journal-title":"Psychol Med"},{"issue":"3","key":"1315_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/2040622315627805","volume":"7","author":"RS McIntyre","year":"2016","unstructured":"McIntyre RS, Woldeyohannes HO, Soczynska JK, Vinberg M, Cha DS, Lee Y, et al. The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Ther Adv Chronic Dis. 2016;7(3):153\u20139. https:\/\/doi.org\/10.1177\/2040622315627805.","journal-title":"Ther Adv Chronic Dis"},{"key":"1315_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244x-13-51","volume":"13","author":"I Romera","year":"2013","unstructured":"Romera I, P\u00e9rez V, Ciudad A, Caballero L, Roca M, Polavieja P, et al. Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry. 2013;13:51. https:\/\/doi.org\/10.1186\/1471-244x-13-51.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"1315_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/wps.20771","volume":"19","author":"M Maj","year":"2020","unstructured":"Maj M, Stein DJ, Parker G, Zimmerman M, Fava GA, De Hert M, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19(3):269\u201393. https:\/\/doi.org\/10.1002\/wps.20771.","journal-title":"World Psychiatry"},{"issue":"4","key":"1315_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","volume":"75","author":"DS Hasin","year":"2018","unstructured":"Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiat. 2018;75(4):336\u201346. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4602.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"1315_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4088\/JCP.13m08961","volume":"75","author":"M Zimmerman","year":"2014","unstructured":"Zimmerman M, Chelminski I, Young D, Dalrymple K, Walsh E, Rosenstein L. A clinically useful self-report measure of the DSM-5 anxious distress specifier for major depressive disorder. J Clin Psychiatry. 2014;75(6):601\u20137. https:\/\/doi.org\/10.4088\/JCP.13m08961.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1315_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120.","journal-title":"World Psychiatry"},{"issue":"5","key":"1315_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2555","volume":"12","author":"CW Espinola","year":"2022","unstructured":"Espinola CW, Khoo Y, Parmar R, Demchenko I, Frey BN, Milev RV, et al. Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. Brain Behav. 2022;12(5):e2555. https:\/\/doi.org\/10.1002\/brb3.2555.","journal-title":"Brain Behav"},{"issue":"4","key":"1315_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4088\/JCP.15m10370","volume":"78","author":"SA Shankman","year":"2017","unstructured":"Shankman SA, Gorka SM, Katz AC, Klein DN, Markowitz JC, Arnow BA, et al. Side effects to antidepressant treatment in patients with depression and comorbid panic disorder. J Clin Psychiatry. 2017;78(4):433\u201340. https:\/\/doi.org\/10.4088\/JCP.15m10370.","journal-title":"J Clin Psychiatry"},{"key":"1315_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jpsychires.2016.09.018","volume":"84","author":"R Gaspersz","year":"2017","unstructured":"Gaspersz R, Lamers F, Kent JM, Beekman ATF, Smit JH, van Hemert AM, et al. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment. J Psychiatr Res. 2017;84:41\u20138. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.09.018.","journal-title":"J Psychiatr Res"},{"key":"1315_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2018.09.027","volume":"243","author":"JD Rosenblat","year":"2019","unstructured":"Rosenblat JD, Simon GE, Sachs GS, Deetz I, Doederlein A, DePeralta D, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2019;243:116\u201320. https:\/\/doi.org\/10.1016\/j.jad.2018.09.027.","journal-title":"J Affect Disord"},{"key":"1315_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4172\/2167-1044.1000237","volume":"5","author":"TM Brown","year":"2016","unstructured":"Brown TM, DiBenedetti DB, Danchenko N, Weiller E, Fava M. Symptoms of anxiety and irritability in patients with major depressive disorder. J Depress Anxiety. 2016;5:237.","journal-title":"J Depress Anxiety."},{"issue":"1","key":"1315_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02935-z","volume":"20","author":"SS Huang","year":"2020","unstructured":"Huang SS, Chen HH, Wang J, Chen WJ, Chen HC, Kuo PH. Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study. BMC Psychiatry. 2020;20(1):541. https:\/\/doi.org\/10.1186\/s12888-020-02935-z.","journal-title":"BMC Psychiatry"},{"issue":"9","key":"1315_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/07067437241245384","volume":"69","author":"RW Lam","year":"2024","unstructured":"Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry. 2024;69(9):641\u201387. https:\/\/doi.org\/10.1177\/07067437241245384.","journal-title":"Can J Psychiatry"},{"key":"1315_CR16","unstructured":"American Psychiatric Association. APA clinical practice guideline for the treatment of patients with major depressive disorder, 3rd edition. 2010; Available from: https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"key":"1315_CR17","unstructured":"US Department of Veteran Affairs. VA\/DoD clinical practice guideline for the management of major depressive disorder. 2022; Available from: https:\/\/www.healthquality.va.gov\/guidelines\/MH\/mdd\/VADODMDDCPGFinal508.pdf"},{"key":"1315_CR18","unstructured":"NICE. NICE guidelines NG222. Depression in adults: treatment and management. 2022; Available from: https:\/\/www.nice.org.uk\/guidance\/ng222"},{"key":"1315_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-9-3","volume":"9","author":"RW Vernooij","year":"2014","unstructured":"Vernooij RW, Sanabria AJ, Sol\u00e0 I, Alonso-Coello P, Mart\u00ednez Garc\u00eda L. Guidance for updating clinical practice guidelines: a systematic review of methodological handbooks. Implement Sci. 2014;9:3. https:\/\/doi.org\/10.1186\/1748-5908-9-3.","journal-title":"Implement Sci"},{"issue":"16","key":"1315_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1503\/cmaj.140547","volume":"186","author":"L Mart\u00ednez Garc\u00eda","year":"2014","unstructured":"Mart\u00ednez Garc\u00eda L, Sanabria AJ, Garc\u00eda Alvarez E, Trujillo-Mart\u00edn MM, Etxeandia-Ikobaltzeta I, Kotzeva A, et al. The validity of recommendations from clinical guidelines: a survival analysis. CMAJ. 2014;186(16):1211\u20139. https:\/\/doi.org\/10.1503\/cmaj.140547.","journal-title":"CMAJ"},{"key":"1315_CR21","unstructured":"American Psychological Association. APA clinical practice guideline for the treatment of depression across three age cohorts. 2019; Available from: https:\/\/www.apa.org\/depression-guideline\/guideline.pdf"},{"issue":"1","key":"1315_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0004867420979353","volume":"55","author":"GS Malhi","year":"2021","unstructured":"Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55(1):7\u2013117. https:\/\/doi.org\/10.1177\/0004867420979353.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"1315_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/nmd.0000000000000767","volume":"206","author":"M Zimmerman","year":"2018","unstructured":"Zimmerman M, Clark H, McGonigal P, Harris L, Guzman Holst C, Martin J. Relationship between the DSM-5 anxious distress specifier and the Hamilton Depression Rating Scale anxiety\/somatization factor. J Nerv Ment Dis. 2018;206(2):152\u20134. https:\/\/doi.org\/10.1097\/nmd.0000000000000767.","journal-title":"J Nerv Ment Dis"},{"key":"1315_CR24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders, fifth edition","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition. Arlington: American Psychiatric Association; 2013."},{"issue":"1","key":"1315_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56\u201362. https:\/\/doi.org\/10.1136\/jnnp.23.1.56.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1315_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/wps.20050","volume":"12","author":"DA Regier","year":"2013","unstructured":"Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: classification and criteria changes. World Psychiatry. 2013;12(2):92\u20138. https:\/\/doi.org\/10.1002\/wps.20050.","journal-title":"World Psychiatry"},{"issue":"12","key":"1315_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0016-3","volume":"7","author":"R Gaspersz","year":"2017","unstructured":"Gaspersz R, Lamers F, Wittenberg G, Beekman ATF, van Hemert AM, Schoevers RA, et al. The role of anxious distress in immune dysregulation in patients with major depressive disorder. Transl Psychiatry. 2017;7(12):1268. https:\/\/doi.org\/10.1038\/s41398-017-0016-3.","journal-title":"Transl Psychiatry"},{"key":"1315_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/ndt.S185815","volume":"15","author":"ME Thase","year":"2019","unstructured":"Thase ME, Weiller E, Zhang P, Weiss C, McIntyre RS. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatr Dis Treat. 2019;15:37\u201345. https:\/\/doi.org\/10.2147\/ndt.S185815.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"1315_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/JCP.0000000000001825","volume":"44","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Bubolic S, Zhang Z, MacKenzie EM, Therrien F, Miguelez M, et al. Effects of adjunctive brexpiprazole on individual depressive symptoms and functioning in patients with major depressive disorder and anxious distress: post hoc analysis of three placebo-controlled studies. J Clin Psychopharmacol. 2024;44(2):133\u201340. https:\/\/doi.org\/10.1097\/JCP.0000000000001825.","journal-title":"J Clin Psychopharmacol"},{"key":"1315_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.comppsych.2017.02.010","volume":"76","author":"M Zimmerman","year":"2017","unstructured":"Zimmerman M, Clark H, McGonigal P, Harris L, Holst CG, Martin J. Reliability and validity of the DSM-5 anxious distress specifier interview. Compr Psychiatry. 2017;76:11\u20137. https:\/\/doi.org\/10.1016\/j.comppsych.2017.02.010.","journal-title":"Compr Psychiatry"},{"key":"1315_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jpsychires.2018.05.006","volume":"103","author":"AJ Rosellini","year":"2018","unstructured":"Rosellini AJ, Bourgeois ML, Correa J, Tung ES, Goncharenko S, Brown TA. Anxious distress in depressed outpatients: prevalence, comorbidity, and incremental validity. J Psychiatr Res. 2018;103:54\u201360. https:\/\/doi.org\/10.1016\/j.jpsychires.2018.05.006.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"1315_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/s1092852923002377","volume":"29","author":"F Bartoli","year":"2024","unstructured":"Bartoli F, Bachi B, Callovini T, Palpella D, Piacenti S, Morreale M, et al. Anxious distress in people with major depressive episodes: a cross-sectional analysis of clinical correlates. CNS Spectr. 2024;29(1):49\u201353. https:\/\/doi.org\/10.1017\/s1092852923002377.","journal-title":"CNS Spectr"},{"issue":"7","key":"1315_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/08039488.2017.1335344","volume":"71","author":"N Maneeton","year":"2017","unstructured":"Maneeton N, Suttajit S, Maneeton B, Likhitsathian S, Eurviyanukul K, Udomratn P, et al. Clinical and socio-demographic correlates of anxious distress in Asian outpatients with major depressive disorder. Nord J Psychiatry. 2017;71(7):503\u20138. https:\/\/doi.org\/10.1080\/08039488.2017.1335344.","journal-title":"Nord J Psychiatry"},{"issue":"4","key":"1315_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/13651501.2021.1907415","volume":"25","author":"T Otsubo","year":"2021","unstructured":"Otsubo T, Hokama C, Sano N, Watanabe Y, Kikuchi T, Tanaka K. How significant is the assessment of the DSM-5 \u2018anxious distress\u2019 specifier in patients with major depressive disorder without comorbid anxiety disorders in the continuation\/maintenance phase? Int J Psychiatry Clin Pract. 2021;25(4):385\u201392. https:\/\/doi.org\/10.1080\/13651501.2021.1907415.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"2","key":"1315_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.9758\/cpn.23.1106","volume":"22","author":"SH Lee","year":"2024","unstructured":"Lee SH, Lee KH, Han TS, Han C, Bahk WM, Lee SJ, et al. The potential role of aripiprazole augmentation for major depressive disorder with anxious distress in naturalistic treatment setting. Clin Psychopharmacol Neurosci. 2024;22(2):370\u20135. https:\/\/doi.org\/10.9758\/cpn.23.1106.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"1315_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jad.2004.11.007","volume":"86","author":"DE Adson","year":"2005","unstructured":"Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86(1):99\u2013104. https:\/\/doi.org\/10.1016\/j.jad.2004.11.007.","journal-title":"J Affect Disord"},{"issue":"10","key":"1315_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.520","volume":"6","author":"LL Davis","year":"2016","unstructured":"Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker RA. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav. 2016;6(10):e00520. https:\/\/doi.org\/10.1002\/brb3.520.","journal-title":"Brain Behav"},{"issue":"2","key":"1315_CR38","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15506","volume":"86","author":"M Fava","year":"2025","unstructured":"Fava M, Masand PS, Maletic V, Chen C, Adams JL, Kerolous M. Efficacy of adjunctive cariprazine on anxiety symptoms in patients with major depressive disorder: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2025;86(2):24m15506. https:\/\/doi.org\/10.4088\/JCP.24m15506.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1315_CR39","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/da.23193","volume":"38","author":"EJ Daly","year":"2021","unstructured":"Daly EJ, Turkoz I, Salvadore G, Fedgchin M, Ionescu DF, Starr HL, et al. The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. Depress Anxiety. 2021;38(11):1120\u201330. https:\/\/doi.org\/10.1002\/da.23193.","journal-title":"Depress Anxiety"},{"issue":"8","key":"1315_CR40","first-page":"579","volume":"38","author":"T Kulhan","year":"2018","unstructured":"Kulhan T, Marcincakova Husarova V, Ondrejka I, Farsky I, Nosalova G. Anxiolytic effects of venlafaxine\/olanzapine combination in treatment of anxious depression. Neuro Endocrinol Lett. 2018;38(8):579\u201385.","journal-title":"Neuro Endocrinol Lett"},{"issue":"7","key":"1315_CR41","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41591-023-02352-1","volume":"29","author":"TD Als","year":"2023","unstructured":"Als TD, Kurki MI, Grove J, Voloudakis G, Therrien K, Tasanko E, et al. Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses. Nat Med. 2023;29(7):1832\u201344. https:\/\/doi.org\/10.1038\/s41591-023-02352-1.","journal-title":"Nat Med"},{"key":"1315_CR42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jad.2017.06.006","volume":"221","author":"ES Winer","year":"2017","unstructured":"Winer ES, Bryant J, Bartoszek G, Rojas E, Nadorff MR, Kilgore J. Mapping the relationship between anxiety, anhedonia, and depression. J Affect Disord. 2017;221:289\u201396. https:\/\/doi.org\/10.1016\/j.jad.2017.06.006.","journal-title":"J Affect Disord"},{"key":"1315_CR43","doi-asserted-by":"publisher","first-page":"1598130","DOI":"10.1155\/2016\/1598130","volume":"2016","author":"L Grillo","year":"2016","unstructured":"Grillo L. A possible role of anhedonia as common substrate for depression and anxiety. Depress Res Treat. 2016;2016:1598130. https:\/\/doi.org\/10.1155\/2016\/1598130.","journal-title":"Depress Res Treat"},{"issue":"10","key":"1315_CR44","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/da.22541","volume":"33","author":"NA Crane","year":"2016","unstructured":"Crane NA, Jenkins LM, Dion C, Meyers KK, Weldon AL, Gabriel LB, et al. Comorbid anxiety increases cognitive control activation in major depressive disorder. Depress Anxiety. 2016;33(10):967\u201377. https:\/\/doi.org\/10.1002\/da.22541.","journal-title":"Depress Anxiety"},{"issue":"1","key":"1315_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/yco.0000000000000376","volume":"31","author":"R Gaspersz","year":"2018","unstructured":"Gaspersz R, Nawijn L, Lamers F, Penninx B. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31(1):17\u201325. https:\/\/doi.org\/10.1097\/yco.0000000000000376.","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"1315_CR46","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/da.22095","volume":"30","author":"DF Ionescu","year":"2013","unstructured":"Ionescu DF, Niciu MJ, Mathews DC, Richards EM, Zarate CA Jr. Neurobiology of anxious depression: a review. Depress Anxiety. 2013;30(4):374\u201385. https:\/\/doi.org\/10.1002\/da.22095.","journal-title":"Depress Anxiety"},{"issue":"3","key":"1315_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1017\/neu.2014.46","volume":"27","author":"DF Ionescu","year":"2015","unstructured":"Ionescu DF, Nugent AC, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA, et al. Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography. Acta Neuropsychiatr. 2015;27(3):143\u201352. https:\/\/doi.org\/10.1017\/neu.2014.46.","journal-title":"Acta Neuropsychiatr"},{"issue":"7","key":"1315_CR48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/da.23264","volume":"39","author":"L Nawijn","year":"2022","unstructured":"Nawijn L, Dinga R, Aghajani M, van Tol MJ, van der Wee NJA, Wunder A, et al. Neural correlates of anxious distress in depression: a neuroimaging study of reactivity to emotional faces and resting-state functional connectivity. Depress Anxiety. 2022;39(7):573\u201385. https:\/\/doi.org\/10.1002\/da.23264.","journal-title":"Depress Anxiety"},{"key":"1315_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00381","volume":"11","author":"X Shao","year":"2020","unstructured":"Shao X, Zhu G. Associations among monoamine neurotransmitter pathways, personality traits, and major depressive disorder. Front Psychiatry. 2020;11:381. https:\/\/doi.org\/10.3389\/fpsyt.2020.00381.","journal-title":"Front Psychiatry"},{"issue":"9","key":"1315_CR50","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1177\/1535370221991830","volume":"246","author":"NC Delva","year":"2021","unstructured":"Delva NC, Stanwood GD. Dysregulation of brain dopamine systems in major depressive disorder. Exp Biol Med (Maywood). 2021;246(9):1084\u201393. https:\/\/doi.org\/10.1177\/1535370221991830.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"10","key":"1315_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101203","volume":"15","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zou D, Li Y, Gu S, Dong J, Ma X, et al. Monoamine neurotransmitters control basic emotions and affect major depressive disorders. Pharmaceuticals (Basel). 2022;15(10):1203. https:\/\/doi.org\/10.3390\/ph15101203.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"1315_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102378","volume":"10","author":"H Zhang","year":"2022","unstructured":"Zhang H, Cui M, Cao JL, Han MH. The role of beta-adrenergic receptors in depression and resilience. Biomedicines. 2022;10(10):2378. https:\/\/doi.org\/10.3390\/biomedicines10102378.","journal-title":"Biomedicines."},{"key":"1315_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2023.1173326","volume":"17","author":"NN Bouras","year":"2023","unstructured":"Bouras NN, Mack NR, Gao WJ. Prefrontal modulation of anxiety through a lens of noradrenergic signaling. Front Syst Neurosci. 2023;17:1173326. https:\/\/doi.org\/10.3389\/fnsys.2023.1173326.","journal-title":"Front Syst Neurosci"},{"key":"1315_CR54","doi-asserted-by":"publisher","first-page":"239821282093032","DOI":"10.1177\/2398212820930321","volume":"4","author":"LS Morris","year":"2020","unstructured":"Morris LS, McCall JG, Charney DS, Murrough JW. The role of the locus coeruleus in the generation of pathological anxiety. Brain Neurosci Adv. 2020;4:2398212820930321. https:\/\/doi.org\/10.1177\/2398212820930321.","journal-title":"Brain Neurosci Adv."},{"key":"1315_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2023.1124112","volume":"15","author":"J Lin","year":"2023","unstructured":"Lin J, Liu W, Guan J, Cui J, Shi R, Wang L, et al. Latest updates on the serotonergic system in depression and anxiety. Front Synaptic Neurosci. 2023;15:1124112. https:\/\/doi.org\/10.3389\/fnsyn.2023.1124112.","journal-title":"Front Synaptic Neurosci"},{"issue":"2","key":"1315_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020148","volume":"14","author":"GR Villas-Boas","year":"2021","unstructured":"Villas-Boas GR, Lavorato SN, Paes MM, de Carvalho PMG, Rescia VC, Cunha MS, et al. Modulation of the serotonergic receptosome in the treatment of anxiety and depression: a narrative review of the experimental evidence. Pharmaceuticals (Basel). 2021;14(2):148. https:\/\/doi.org\/10.3390\/ph14020148.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"1315_CR57","doi-asserted-by":"publisher","first-page":"295","DOI":"10.24869\/psyd.2025.295","volume":"37","author":"S Mansour","year":"2025","unstructured":"Mansour S, Abdelrahman S, Banwari G. Dopamine dysfunction beyond psychosis: reevaluating its role in depression, anxiety, and obsessive-compulsive disorder. Psychiatr Danub. 2025;37(3):295\u2013309. https:\/\/doi.org\/10.24869\/psyd.2025.295.","journal-title":"Psychiatr Danub"},{"key":"1315_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cpr.2018.07.005","volume":"64","author":"JEJ Buckman","year":"2018","unstructured":"Buckman JEJ, Underwood A, Clarke K, Saunders R, Hollon SD, Fearon P, et al. Risk factors for relapse and recurrence of depression in adults and how they operate: a four-phase systematic review and meta-synthesis. Clin Psychol Rev. 2018;64:13\u201338. https:\/\/doi.org\/10.1016\/j.cpr.2018.07.005.","journal-title":"Clin Psychol Rev"},{"key":"1315_CR59","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jad.2023.01.074","volume":"328","author":"M Adair","year":"2023","unstructured":"Adair M, Christensen MC, Florea I, Loft H, Fagiolini A. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: an updated analysis of efficacy and tolerability. J Affect Disord. 2023;328:345\u201354. https:\/\/doi.org\/10.1016\/j.jad.2023.01.074.","journal-title":"J Affect Disord"},{"issue":"2","key":"1315_CR60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/02698811241309612","volume":"39","author":"I Berardelli","year":"2025","unstructured":"Berardelli I, Rogante E, Formica F, Iannazzo R, Mammoliti AV, Riccioni R, et al. The efficacy of vortioxetine in the acute treatment of major depressive disorder: a systematic review and meta-analysis. J Psychopharmacol. 2025;39(2):92\u2013105. https:\/\/doi.org\/10.1177\/02698811241309612.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"1315_CR61","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000524400","volume":"91","author":"SL Dubovsky","year":"2022","unstructured":"Dubovsky SL, Marshall D. Benzodiazepines remain important therapeutic options in psychiatric practice. Psychother Psychosom. 2022;91(5):307\u201334. https:\/\/doi.org\/10.1159\/000524400.","journal-title":"Psychother Psychosom"},{"issue":"6","key":"1315_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001026.pub2","volume":"6","author":"Y Ogawa","year":"2019","unstructured":"Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 2019;6(6):Cd001026. https:\/\/doi.org\/10.1002\/14651858.CD001026.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1315_CR63","unstructured":"Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4-7"},{"issue":"1","key":"1315_CR64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.neuron.2012.09.011","volume":"76","author":"SJ Sara","year":"2012","unstructured":"Sara SJ, Bouret S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neuron. 2012;76(1):130\u201341. https:\/\/doi.org\/10.1016\/j.neuron.2012.09.011.","journal-title":"Neuron"},{"issue":"1","key":"1315_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/pcn.12126","volume":"68","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto K, Shinba T, Yoshii M. Psychiatric symptoms of noradrenergic dysfunction: a pathophysiological view. Psychiatry Clin Neurosci. 2014;68(1):1\u201320. https:\/\/doi.org\/10.1111\/pcn.12126.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"1315_CR66","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrn2648","volume":"10","author":"AF Arnsten","year":"2009","unstructured":"Arnsten AF. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009;10(6):410\u201322. https:\/\/doi.org\/10.1038\/nrn2648.","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"1315_CR67","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41583-020-0360-9","volume":"21","author":"GR Poe","year":"2020","unstructured":"Poe GR, Foote S, Eschenko O, Johansen JP, Bouret S, Aston-Jones G, et al. Locus coeruleus: a new look at the blue spot. Nat Rev Neurosci. 2020;21(11):644\u201359. https:\/\/doi.org\/10.1038\/s41583-020-0360-9.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"1315_CR68","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.plunaro2417ah","volume":"85","author":"R Jain","year":"2024","unstructured":"Jain R, Chepke C, Davis LL, McIntyre RS, Raskind MA. Dysregulation of noradrenergic activity: its role in conceptualizing and treating major depressive disorder, schizophrenia, agitation in Alzheimer\u2019s disease, and posttraumatic stress disorder. J Clin Psychiatry. 2024;85(4):plunaro2417ah. https:\/\/doi.org\/10.4088\/JCP.plunaro2417ah.","journal-title":"J Clin Psychiatry"},{"key":"1315_CR69","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2147\/ndt.S111818","volume":"12","author":"T Sternat","year":"2016","unstructured":"Sternat T, Katzman MA. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat. 2016;12:2149\u201364. https:\/\/doi.org\/10.2147\/ndt.S111818.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1315_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2017.00042","volume":"8","author":"V Maletic","year":"2017","unstructured":"Maletic V, Eramo A, Gwin K, Offord SJ, Duffy RA. The role of norepinephrine and its \u03b1-adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: a systematic review. Front Psychiatry. 2017;8:42. https:\/\/doi.org\/10.3389\/fpsyt.2017.00042.","journal-title":"Front Psychiatry"},{"issue":"3","key":"1315_CR71","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.pharmthera.2006.11.006","volume":"113","author":"BP Ramos","year":"2007","unstructured":"Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007;113(3):523\u201336. https:\/\/doi.org\/10.1016\/j.pharmthera.2006.11.006.","journal-title":"Pharmacol Ther"},{"key":"1315_CR72","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/ndt.S91311","volume":"12","author":"A Montoya","year":"2016","unstructured":"Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat. 2016;12:541\u201357. https:\/\/doi.org\/10.2147\/ndt.S91311.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1315_CR73","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fpsyt.2017.00144","volume":"8","author":"MM Uys","year":"2017","unstructured":"Uys MM, Shahid M, Harvey BH. Therapeutic potential of selectively targeting the \u03b12C-adrenoceptor in cognition, depression, and schizophrenia - new developments and future perspective. Front Psychiatry. 2017;8:144. https:\/\/doi.org\/10.3389\/fpsyt.2017.00144.","journal-title":"Front Psychiatry."},{"key":"1315_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2014.00199","volume":"8","author":"PR Albert","year":"2014","unstructured":"Albert PR, Vahid-Ansari F, Luckhart C. Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. Front Behav Neurosci. 2014;8:199. https:\/\/doi.org\/10.3389\/fnbeh.2014.00199.","journal-title":"Front Behav Neurosci"},{"key":"1315_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2013.00040","volume":"7","author":"T Maejima","year":"2013","unstructured":"Maejima T, Masseck OA, Mark MD, Herlitze S. Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channels. Front Integr Neurosci. 2013;7:40. https:\/\/doi.org\/10.3389\/fnint.2013.00040.","journal-title":"Front Integr Neurosci"},{"issue":"1","key":"1315_CR76","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/pr.118.015552","volume":"73","author":"NM Barnes","year":"2021","unstructured":"Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, et al. International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function. Pharmacol Rev. 2021;73(1):310\u2013520. https:\/\/doi.org\/10.1124\/pr.118.015552.","journal-title":"Pharmacol Rev"},{"key":"1315_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135378","volume":"738","author":"AK Radke","year":"2020","unstructured":"Radke AK, Piantadosi PT, Uhl GR, Hall FS, Holmes A. Improved visual discrimination learning in mice with partial 5-HT2B gene deletion. Neurosci Lett. 2020;738:135378. https:\/\/doi.org\/10.1016\/j.neulet.2020.135378.","journal-title":"Neurosci Lett"},{"issue":"8","key":"1315_CR78","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/sj.bjp.0705887","volume":"142","author":"S Kantor","year":"2004","unstructured":"Kantor S, Jakus R, Balogh B, Benko A, Bagdy G. Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505. Br J Pharmacol. 2004;142(8):1332\u201342. https:\/\/doi.org\/10.1038\/sj.bjp.0705887.","journal-title":"Br J Pharmacol"},{"key":"1315_CR79","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3389\/fphar.2019.00404","volume":"10","author":"SA Torrisi","year":"2019","unstructured":"Torrisi SA, Leggio GM, Drago F, Salomone S. Therapeutic challenges of post-traumatic stress disorder: focus on the dopaminergic system. Front Pharmacol. 2019;10:404. https:\/\/doi.org\/10.3389\/fphar.2019.00404.","journal-title":"Front Pharmacol"},{"issue":"16","key":"1315_CR80","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.cub.2012.05.053","volume":"22","author":"T Sharot","year":"2012","unstructured":"Sharot T, Guitart-Masip M, Korn CW, Chowdhury R, Dolan RJ. How dopamine enhances an optimism bias in humans. Curr Biol. 2012;22(16):1477\u201381. https:\/\/doi.org\/10.1016\/j.cub.2012.05.053.","journal-title":"Curr Biol"},{"issue":"10","key":"1315_CR81","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.euroneuro.2017.08.427","volume":"27","author":"M Peci\u00f1a","year":"2017","unstructured":"Peci\u00f1a M, Sikora M, Avery ET, Heffernan J, Peci\u00f1a S, Mickey BJ, et al. Striatal dopamine D2\/3 receptor-mediated neurotransmission in major depression: implications for anhedonia, anxiety and treatment response. Eur Neuropsychopharmacol. 2017;27(10):977\u201386. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.08.427.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"1315_CR82","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/2045125316672136","volume":"7","author":"JS Frankel","year":"2017","unstructured":"Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7(1):29\u201341. https:\/\/doi.org\/10.1177\/2045125316672136.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1315_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.947785","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao F, Cheng Z, Piao J, Cui R, Li B. Dopamine receptors: is it possible to become a therapeutic target for depression? Front Pharmacol. 2022;13:947785. https:\/\/doi.org\/10.3389\/fphar.2022.947785.","journal-title":"Front Pharmacol"},{"issue":"Suppl","key":"1315_CR84","first-page":"S3","volume":"26","author":"P Blier","year":"2001","unstructured":"Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci. 2001;26(Suppl):S3\u201310.","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"1315_CR85","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1139\/jpn.0930","volume":"34","author":"E Dremencov","year":"2009","unstructured":"Dremencov E, El Mansari M, Blier P. Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci. 2009;34(3):223\u20139.","journal-title":"J Psychiatry Neurosci"},{"issue":"12","key":"1315_CR86","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.4088\/JCP.v69n1211","volume":"69","author":"MH Trivedi","year":"2008","unstructured":"Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008;69(12):1928\u201336.","journal-title":"J Clin Psychiatry"},{"key":"1315_CR87","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2016.05.013","volume":"201","author":"RS McIntyre","year":"2016","unstructured":"McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomised controlled trials. J Affect Disord. 2016;201:116\u201323. https:\/\/doi.org\/10.1016\/j.jad.2016.05.013.","journal-title":"J Affect Disord"},{"issue":"8","key":"1315_CR88","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.4088\/jcp.v69n0812","volume":"69","author":"GI Papakostas","year":"2008","unstructured":"Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008;69(8):1287\u201392. https:\/\/doi.org\/10.4088\/jcp.v69n0812.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1315_CR89","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychires.2007.05.012","volume":"42","author":"GI Papakostas","year":"2008","unstructured":"Papakostas GI, Trivedi MH, Alpert JE, Seifert CA, Krishen A, Goodale EP, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res. 2008;42(2):134\u201340. https:\/\/doi.org\/10.1016\/j.jpsychires.2007.05.012.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"1315_CR90","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/0269881120954048","volume":"35","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rodrigues NB, Lipsitz O, Nasri F, Gill H, Lui LM, et al. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: results from the Canadian Rapid Treatment Center of Excellence. J Psychopharmacol. 2021;35(2):128\u201336. https:\/\/doi.org\/10.1177\/0269881120954048.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1315_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2023-101007","volume":"36","author":"X Lan","year":"2023","unstructured":"Lan X, Wang C, Zhang F, Liu H, Fu L, Li W, et al. Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression. Gen Psychiatr. 2023;36(3):e101007. https:\/\/doi.org\/10.1136\/gpsych-2023-101007.","journal-title":"Gen Psychiatr"},{"issue":"4","key":"1315_CR92","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1017\/s1092852920001194","volume":"26","author":"MH Chen","year":"2021","unstructured":"Chen MH, Lin WC, Wu HJ, Bai YM, Li CT, Tsai SJ, et al. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression. CNS Spectr. 2021;26(4):362\u20137. https:\/\/doi.org\/10.1017\/s1092852920001194.","journal-title":"CNS Spectr"},{"key":"1315_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2019.08.012","volume":"259","author":"W Liu","year":"2019","unstructured":"Liu W, Zhou Y, Zheng W, Wang C, Zhan Y, Lan X, et al. Repeated intravenous infusions of ketamine: neurocognition in patients with anxious and nonanxious treatment-resistant depression. J Affect Disord. 2019;259:1\u20136. https:\/\/doi.org\/10.1016\/j.jad.2019.08.012.","journal-title":"J Affect Disord"},{"issue":"3","key":"1315_CR94","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/da.22875","volume":"36","author":"NC Salloum","year":"2019","unstructured":"Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, et al. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019;36(3):235\u201343. https:\/\/doi.org\/10.1002\/da.22875.","journal-title":"Depress Anxiety"},{"issue":"9","key":"1315_CR95","doi-asserted-by":"publisher","first-page":"e932","DOI":"10.4088\/JCP.14m09049","volume":"75","author":"DF Ionescu","year":"2014","unstructured":"Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):e932\u20138. https:\/\/doi.org\/10.4088\/JCP.14m09049.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1315_CR96","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0269881120978398","volume":"35","author":"AC Lucchese","year":"2021","unstructured":"Lucchese AC, Sarin LM, Magalh\u00e3es EJM, Del Sant LC, C BP, Tuena MA, et al. Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. J Psychopharmacol. 2021;35(2):142\u20139. https:\/\/doi.org\/10.1177\/0269881120978398.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"1315_CR97","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/da.21970","volume":"29","author":"ME Thase","year":"2012","unstructured":"Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574\u201386. https:\/\/doi.org\/10.1002\/da.21970.","journal-title":"Depress Anxiety"},{"issue":"2","key":"1315_CR98","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/15622975.2013.842654","volume":"15","author":"B Bandelow","year":"2014","unstructured":"Bandelow B, Bauer M, Vieta E, El-Khalili N, Gustafsson U, Earley WR, et al. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry. 2014;15(2):155\u201366. https:\/\/doi.org\/10.3109\/15622975.2013.842654.","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"1315_CR99","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/yic.0000000000000007","volume":"29","author":"SA Montgomery","year":"2014","unstructured":"Montgomery SA, Altamura AC, Katila H, Datto C, Szamosi J, Eriksson H. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels. Int Clin Psychopharmacol. 2014;29(2):93\u2013105. https:\/\/doi.org\/10.1097\/yic.0000000000000007.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"1315_CR100","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14096","volume":"83","author":"N Ravindran","year":"2022","unstructured":"Ravindran N, McKay M, Paric A, Johnson S, Chandrasena R, Abraham G, et al. Randomized, placebo-controlled effectiveness study of quetiapine XR in comorbid depressive and anxiety disorders. J Clin Psychiatry. 2022;83(3):21m14096. https:\/\/doi.org\/10.4088\/JCP.21m14096.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1315_CR101","doi-asserted-by":"publisher","first-page":"8","DOI":"10.64719\/pb.4339","volume":"46","author":"R Li","year":"2016","unstructured":"Li R, Wu R, Chen J, Kemp DE, Ren M, Conroy C, et al. A randomized, placebo-controlled pilot study of quetiapine-XR monotherapy or adjunctive therapy to antidepressant in acute major depressive disorder with current generalized anxiety disorder. Psychopharmacol Bull. 2016;46(1):8\u201323.","journal-title":"Psychopharmacol Bull"},{"issue":"7","key":"1315_CR102","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/da.20275","volume":"24","author":"A McIntyre","year":"2007","unstructured":"McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487\u201394. https:\/\/doi.org\/10.1002\/da.20275.","journal-title":"Depress Anxiety"},{"key":"1315_CR103","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ndt.S320091","volume":"18","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu X, Peng D, Wu Y, Su Y, Xu J, et al. A preliminary study of different treatment strategies for anxious depression. Neuropsychiatr Dis Treat. 2022;18:11\u20138. https:\/\/doi.org\/10.2147\/ndt.S320091.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"1315_CR104","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1177\/0269881120965939","volume":"34","author":"R Rifkin-Zybutz","year":"2020","unstructured":"Rifkin-Zybutz R, MacNeill S, Davies SJ, Dickens C, Campbell J, Anderson IM, et al. Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial. J Psychopharmacol. 2020;34(12):1342\u20139. https:\/\/doi.org\/10.1177\/0269881120965939.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1315_CR105","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1742-1241.2010.02624.x","volume":"65","author":"JE Kim","year":"2011","unstructured":"Kim JE, Yoon SJ, Kim J, Jung JY, Jeong HS, Cho HB, et al. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract. 2011;65(3):323\u20139. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02624.x.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1315_CR106","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s12325-015-0207-3","volume":"32","author":"RS McIntyre","year":"2015","unstructured":"McIntyre RS, Weiller E. Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study. Adv Ther. 2015;32(5):429\u201344. https:\/\/doi.org\/10.1007\/s12325-015-0207-3.","journal-title":"Adv Ther"},{"key":"1315_CR107","unstructured":"AstraZeneca. Seroquel XR (quetiapine) Prescribing Information. 2022; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022047s046lbl.pdf"},{"key":"1315_CR108","unstructured":"Otsuka Pharmaceutical Co. Ltd. Abilify (aripiprazole) Prescribing Information. 2024; Available from: https:\/\/www.otsuka-us.com\/sites\/g\/files\/qhldwo9046\/files\/media\/static\/Abilify-PI.pdf"},{"key":"1315_CR109","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti (brexpiprazole) Prescribing Information. 2025; Available from: https:\/\/www.otsuka-us.com\/sites\/g\/files\/qhldwo7866\/files\/media\/static\/Rexulti-PI.pdf"},{"key":"1315_CR110","unstructured":"Lilly USA LLC. Zyprexa (olanzapine) Prescribing Information. 2020; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020592s074,021086s048,021253s061lbl.pdf"},{"key":"1315_CR111","unstructured":"Allergan USA Inc. Vraylar Prescribing Information. 2024; Available from: https:\/\/www.rxabbvie.com\/pdf\/vraylar_pi.pdf"},{"issue":"10","key":"1315_CR112","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1586\/14737175.2015.1086269","volume":"15","author":"L Citrome","year":"2015","unstructured":"Citrome L, Stensb\u00f8l TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15(10):1219\u201329. https:\/\/doi.org\/10.1586\/14737175.2015.1086269.","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"1315_CR113","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/pcn.12242","volume":"69","author":"I Kusumi","year":"2015","unstructured":"Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci. 2015;69(5):243\u201358. https:\/\/doi.org\/10.1111\/pcn.12242.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"1315_CR114","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2174\/1570159x15666170630163616","volume":"16","author":"S Siafis","year":"2018","unstructured":"Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic drugs: from receptor-binding profiles to metabolic side effects. Curr Neuropharmacol. 2018;16(8):1210\u201323. https:\/\/doi.org\/10.2174\/1570159x15666170630163616.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"1315_CR115","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.602","volume":"8","author":"RGW Proudman","year":"2020","unstructured":"Proudman RGW, Pupo AS, Baker JG. The affinity and selectivity of \u03b1-adrenoceptor antagonists, antidepressants, and antipsychotics for the human \u03b11A, \u03b11B, and \u03b11D-adrenoceptors. Pharmacol Res Perspect. 2020;8(4):e00602. https:\/\/doi.org\/10.1002\/prp2.602.","journal-title":"Pharmacol Res Perspect"},{"issue":"8","key":"1315_CR116","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400\u201311. https:\/\/doi.org\/10.1038\/sj.npp.1300203.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1315_CR117","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","volume":"52","author":"SM Wang","year":"2016","unstructured":"Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, et al. Second generation antipsychotics in the treatment of major depressive disorder: an update. Chonnam Med J. 2016;52(3):159\u201372. https:\/\/doi.org\/10.4068\/cmj.2016.52.3.159.","journal-title":"Chonnam Med J"},{"issue":"1","key":"1315_CR118","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1017\/neu.2018.23","volume":"31","author":"M Bauer","year":"2019","unstructured":"Bauer M, Hefting N, Lindsten A, Josiassen MK, Hobart M. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder. Acta Neuropsychiatr. 2019;31(1):27\u201335. https:\/\/doi.org\/10.1017\/neu.2018.23.","journal-title":"Acta Neuropsychiatr"},{"issue":"11","key":"1315_CR119","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/npp.2014.101","volume":"39","author":"E Brunner","year":"2014","unstructured":"Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME. Efficacy and safety of olanzapine\/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology. 2014;39(11):2549\u201359. https:\/\/doi.org\/10.1038\/npp.2014.101.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1315_CR120","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/jama.2017.8036","volume":"318","author":"S Mohamed","year":"2017","unstructured":"Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA. 2017;318(2):132\u201345. https:\/\/doi.org\/10.1001\/jama.2017.8036.","journal-title":"JAMA"},{"issue":"11","key":"1315_CR121","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/sj.npp.1301113","volume":"31","author":"MH Rapaport","year":"2006","unstructured":"Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31(11):2505\u201313. https:\/\/doi.org\/10.1038\/sj.npp.1301113.","journal-title":"Neuropsychopharmacology"},{"key":"1315_CR122","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2024.32","volume":"37","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Sundararajan K, Behl S, Hefting N, Jin N, Brewer C, et al. A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder. Acta Neuropsychiatr. 2024:37:e33. https:\/\/doi.org\/10.1017\/neu.2024.32.","journal-title":"Acta Neuropsychiatr"},{"issue":"9","key":"1315_CR123","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","volume":"29","author":"A de Bartolomeis","year":"2015","unstructured":"de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015;29(9):773\u201399. https:\/\/doi.org\/10.1007\/s40263-015-0278-3.","journal-title":"CNS Drugs"},{"issue":"3","key":"1315_CR124","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604. https:\/\/doi.org\/10.1124\/jpet.114.213793.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1315_CR125","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4088\/pcc.v06n0403","volume":"6","author":"SM Stahl","year":"2004","unstructured":"Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159\u201366. https:\/\/doi.org\/10.4088\/pcc.v06n0403.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"1315_CR126","doi-asserted-by":"publisher","first-page":"1394787","DOI":"10.3389\/fpsyt.2024.1394787","volume":"15","author":"M Di Vincenzo","year":"2024","unstructured":"Di Vincenzo M, Martiadis V, Della Rocca B, Arsenio E, D\u2019Arpa A, Volpicelli A, et al. Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review. Front Psychiatry. 2024;15:1394787. https:\/\/doi.org\/10.3389\/fpsyt.2024.1394787.","journal-title":"Front Psychiatry."},{"issue":"2","key":"1315_CR127","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53987","volume":"16","author":"S Kumari","year":"2024","unstructured":"Kumari S, Chaudhry HA, Sagot A, Doumas S, Abdullah H, Alcera E, et al. Exploring esketamine\u2019s therapeutic outcomes as an FDA-designated breakthrough for treatment-resistant depression and major depressive disorder with suicidal intent: a narrative review. Cureus. 2024;16(2):e53987. https:\/\/doi.org\/10.7759\/cureus.53987.","journal-title":"Cureus"},{"issue":"8","key":"1315_CR128","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bdi.12941","volume":"22","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Lipsitz O, Rodrigues NB, Lee Y, Cha DS, Vinberg M, et al. The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord. 2020;22(8):831\u201340. https:\/\/doi.org\/10.1111\/bdi.12941.","journal-title":"Bipolar Disord"},{"key":"1315_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115378","volume":"327","author":"M Pettorruso","year":"2023","unstructured":"Pettorruso M, Guidotti R, d\u2019Andrea G, De Risio L, D\u2019Andrea A, Chiappini S, et al. Predicting outcome with intranasal esketamine treatment: a machine-learning, three-month study in treatment-resistant depression (ESK-LEARNING). Psychiatry Res. 2023;327:115378. https:\/\/doi.org\/10.1016\/j.psychres.2023.115378.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1315_CR130","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40263-013-0039-0","volume":"27","author":"GS Malhi","year":"2013","unstructured":"Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013;27(2):135\u201353. https:\/\/doi.org\/10.1007\/s40263-013-0039-0.","journal-title":"CNS Drugs"},{"key":"1315_CR131","unstructured":"Jilani TN, Gibbons JR, Faizy RM, Saadabadi A. Mirtazapine. StatPearls. Treasure Island (FL) ineligible companies.: StatPearls Publishing LLC.; 2024."},{"key":"1315_CR132","doi-asserted-by":"publisher","DOI":"10.1017\/9781108975292","volume-title":"Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications","author":"SM Stahl","year":"2021","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications. 5th ed. New York: Cambridge University Press; 2021.","edition":"5"},{"issue":"11","key":"1315_CR133","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1001\/jama.2009.351","volume":"301","author":"ND Volkow","year":"2009","unstructured":"Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148\u201354. https:\/\/doi.org\/10.1001\/jama.2009.351.","journal-title":"JAMA"},{"issue":"2","key":"1315_CR134","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/s1461145700001875","volume":"3","author":"ME Newman","year":"2000","unstructured":"Newman ME, Agid O, Gur E, Lerer B. Pharmacological mechanisms of T3 augmentation of antidepressant action. Int J Neuropsychopharmacol. 2000;3(2):187\u201391. https:\/\/doi.org\/10.1017\/s1461145700001875.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"1315_CR135","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","volume":"27","author":"P Celada","year":"2013","unstructured":"Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27(9):703\u201316. https:\/\/doi.org\/10.1007\/s40263-013-0071-0.","journal-title":"CNS Drugs"},{"issue":"1","key":"1315_CR136","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13041-017-0306-y","volume":"10","author":"CN Yohn","year":"2017","unstructured":"Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Mol Brain. 2017;10(1):28. https:\/\/doi.org\/10.1186\/s13041-017-0306-y.","journal-title":"Mol Brain"},{"issue":"3","key":"1315_CR137","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1124\/jpet.114.213819","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605\u201314. https:\/\/doi.org\/10.1124\/jpet.114.213819.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1315_CR138","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40801-022-00316-4","volume":"9","author":"R Jain","year":"2022","unstructured":"Jain R, Higa S, Keyloun K, Park J, Bonafede M, Tung A, et al. Treatment patterns during major depressive episodes among patients with major depressive disorder: a retrospective database analysis. Drugs Real World Outcomes. 2022;9(3):477\u201386. https:\/\/doi.org\/10.1007\/s40801-022-00316-4.","journal-title":"Drugs Real World Outcomes"},{"issue":"2","key":"1315_CR139","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/jcp.0000000000000665","volume":"37","author":"L Citrome","year":"2017","unstructured":"Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37(2):138\u201347. https:\/\/doi.org\/10.1097\/jcp.0000000000000665.","journal-title":"J Clin Psychopharmacol"},{"issue":"38","key":"1315_CR140","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000034670","volume":"102","author":"J Wang","year":"2023","unstructured":"Wang J, Li W, Li M, Wu H, Qiu Z. Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: a systematic review and network meta-analysis. Medicine (Baltimore). 2023;102(38):e34670. https:\/\/doi.org\/10.1097\/md.0000000000034670.","journal-title":"Medicine (Baltimore)"},{"key":"1315_CR141","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.lu18052ah1","author":"LL Citrome","year":"2019","unstructured":"Citrome LL, McIntyre RS, Manning JS, McIntosh D. Activating and sedating properties of medications used for the treatment of major depressive disorder and their effect on patient functioning. J Clin Psychiatry. 2019. https:\/\/doi.org\/10.4088\/JCP.lu18052ah1.","journal-title":"J Clin Psychiatry"},{"key":"1315_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116641","volume":"351","author":"S Reeve","year":"2025","unstructured":"Reeve S, Robbins K, Hodgekins J. The psychological consequences of the sedating side effects of antipsychotic medication: a systematic review. Psychiatry Res. 2025;351:116641. https:\/\/doi.org\/10.1016\/j.psychres.2025.116641.","journal-title":"Psychiatry Res"},{"issue":"1","key":"1315_CR143","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"HA Nasrallah","year":"2008","unstructured":"Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27\u201335. https:\/\/doi.org\/10.1038\/sj.mp.4002066.","journal-title":"Mol Psychiatry"},{"issue":"12","key":"1315_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008121.pub2","volume":"2010","author":"K Komossa","year":"2010","unstructured":"Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;2010(12):Cd008121. https:\/\/doi.org\/10.1002\/14651858.CD008121.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1315_CR145","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.4088\/JCP.ot17015ah1","volume":"78","author":"ME Thase","year":"2017","unstructured":"Thase ME, Weisler RH, Manning JS, Trivedi MH. Utilizing the DSM-5 anxious distress specifier to develop treatment strategies for patients with major depressive disorder. J Clin Psychiatry. 2017;78(9):1351\u201362. https:\/\/doi.org\/10.4088\/JCP.ot17015ah1.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1315_CR146","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4088\/JCP.15m10221","volume":"78","author":"R Gaspersz","year":"2017","unstructured":"Gaspersz R, Lamers F, Kent JM, Beekman AT, Smit JH, van Hemert AM, et al. Longitudinal predictive validity of the DSM-5 anxious distress specifier for clinical outcomes in a large cohort of patients with major depressive disorder. J Clin Psychiatry. 2017;78(2):207\u201313. https:\/\/doi.org\/10.4088\/JCP.15m10221.","journal-title":"J Clin Psychiatry"},{"key":"1315_CR147","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.brainres.2009.06.035","volume":"1285","author":"VA Doze","year":"2009","unstructured":"Doze VA, Handel EM, Jensen KA, Darsie B, Luger EJ, Haselton JR, et al. Alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Res. 2009;1285:148\u201357. https:\/\/doi.org\/10.1016\/j.brainres.2009.06.035.","journal-title":"Brain Res"},{"issue":"4","key":"1315_CR148","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bcpt.12090","volume":"113","author":"J Sallinen","year":"2013","unstructured":"Sallinen J, Holappa J, Koivisto A, Kuokkanen K, Chapman H, Lehtim\u00e4ki J, et al. Pharmacological characterisation of a structurally novel \u03b12C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol. 2013;113(4):239\u201349. https:\/\/doi.org\/10.1111\/bcpt.12090.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1315_CR149","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0006-3223(01)01262-8","volume":"51","author":"LL Carpenter","year":"2002","unstructured":"Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183\u20138. https:\/\/doi.org\/10.1016\/s0006-3223(01)01262-8.","journal-title":"Biol Psychiatry"},{"key":"1315_CR150","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jpsychires.2017.02.003","volume":"89","author":"M Kato","year":"2017","unstructured":"Kato M, Takekita Y, Koshikawa Y, Sakai S, Bandou H, Nishida K, et al. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. J Psychiatr Res. 2017;89:97\u2013104. https:\/\/doi.org\/10.1016\/j.jpsychires.2017.02.003.","journal-title":"J Psychiatr Res"},{"issue":"1-2","key":"1315_CR151","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejphar.2005.12.008","volume":"532","author":"X Li","year":"2006","unstructured":"Li X, Inoue T, Abekawa T, Weng S, Nakagawa S, Izumi T, et al. 5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala. Eur J Pharmacol. 2006;532(1\u20132):74\u201380. https:\/\/doi.org\/10.1016\/j.ejphar.2005.12.008.","journal-title":"Eur J Pharmacol"},{"issue":"15","key":"1315_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158814","volume":"23","author":"NK Popova","year":"2022","unstructured":"Popova NK, Tsybko AS, Naumenko VS. The implication of 5-HT receptor family members in aggression, depression and suicide: similarity and difference. Int J Mol Sci. 2022;23(15):8814.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1315_CR153","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/ijnp\/pyab040","volume":"24","author":"SM Hags\u00e4ter","year":"2021","unstructured":"Hags\u00e4ter SM, Pettersson R, Pettersson C, Atanasovski D, N\u00e4slund J, Eriksson E. A complex impact of systemically administered 5-HT2A receptor ligands on conditioned fear. Int J Neuropsychopharmacol. 2021;24(9):749\u201357. https:\/\/doi.org\/10.1093\/ijnp\/pyab040.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1315_CR154","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/nss.s6849","volume":"2","author":"KE Vanover","year":"2010","unstructured":"Vanover KE, Davis RE. Role of 5-HT2A receptor antagonists in the treatment of insomnia. Nat Sci Sleep. 2010;2:139\u201350. https:\/\/doi.org\/10.2147\/nss.s6849.","journal-title":"Nat Sci Sleep."},{"key":"1315_CR155","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.brainres.2016.04.073","volume":"1643","author":"BB de Paula","year":"2016","unstructured":"de Paula BB, Leite-Panissi CR. Distinct effect of 5-HT1A and 5-HT2A receptors in the medial nucleus of the amygdala on tonic immobility behavior. Brain Res. 2016;1643:152\u20138. https:\/\/doi.org\/10.1016\/j.brainres.2016.04.073.","journal-title":"Brain Res"},{"issue":"4","key":"1315_CR156","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","volume":"18","author":"JA Lieberman","year":"2004","unstructured":"Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251\u201367. https:\/\/doi.org\/10.2165\/00023210-200418040-00005.","journal-title":"CNS Drugs"},{"issue":"2","key":"1315_CR157","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40263-018-0494-8","volume":"32","author":"K Stegmayer","year":"2018","unstructured":"Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018;32(2):135\u201347. https:\/\/doi.org\/10.1007\/s40263-018-0494-8.","journal-title":"CNS Drugs"},{"issue":"7","key":"1315_CR158","first-page":"802","volume":"11","author":"A Newman-Tancredi","year":"2010","unstructured":"Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11(7):802\u201312.","journal-title":"Curr Opin Investig Drugs"},{"issue":"5","key":"1315_CR159","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1017\/s1461145713001417","volume":"17","author":"ZG Laoutidis","year":"2014","unstructured":"Laoutidis ZG, Luckhaus C. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014;17(5):823\u201332. https:\/\/doi.org\/10.1017\/s1461145713001417.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"1315_CR160","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12174","volume":"79","author":"C Blanco","year":"2018","unstructured":"Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. J Clin Psychiatry. 2018;79(6):18m12174. https:\/\/doi.org\/10.4088\/JCP.18m12174.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"1315_CR161","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapsychiatry.2017.1273","volume":"74","author":"GA Bushnell","year":"2017","unstructured":"Bushnell GA, St\u00fcrmer T, Gaynes BN, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA Psychiat. 2017;74(7):747\u201355. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1273.","journal-title":"JAMA Psychiat"},{"key":"1315_CR162","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jad.2024.07.142","volume":"363","author":"C Wang","year":"2024","unstructured":"Wang C, Wang X, Wang J, Li X, Lu D, Guo F, et al. Prevalence and clinical correlates of benzodiazepine use in the patients with major depressive disorder. J Affect Disord. 2024;363:619\u201325. https:\/\/doi.org\/10.1016\/j.jad.2024.07.142.","journal-title":"J Affect Disord"},{"issue":"1","key":"1315_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02514-2","volume":"13","author":"AJ Cutler","year":"2023","unstructured":"Cutler AJ, Mattingly GW, Maletic V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl Psychiatry. 2023;13(1):228. https:\/\/doi.org\/10.1038\/s41398-023-02514-2.","journal-title":"Transl Psychiatry"},{"issue":"6","key":"1315_CR164","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1192\/bja.2020.17","volume":"26","author":"A de Cates","year":"2020","unstructured":"de Cates A, De Giorgi R. Antidepressants plus benzodiazepines in major depressive disorder: a clinical dilemma with no recent answers from research. BJPsych Adv. 2020;26(6):321\u20136. https:\/\/doi.org\/10.1192\/bja.2020.17.","journal-title":"BJPsych Adv."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01315-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01315-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01315-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:28:48Z","timestamp":1786948128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01315-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":164,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01315-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was financially supported by Otsuka Canada Pharmaceuticals Inc. (Saint-Laurent, Quebec, Canada) and Lundbeck Canada Inc. (Saint-Laurent, Quebec, Canada). The sponsors were involved as authors in the concept development of this narrative review, the writing and reviewing of this article, and the decision to submit the article for publication. The sponsors paid the open access fee.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Roger S. McIntyre has received research grant support from CIHR\/GACD\/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker\/consultation fees from Lundbeck, Janssen, Johnson & Johnson, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Sage, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, MindMed, Neurocrine, Neurawell, Supernus, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie and Atai Life Sciences. Masaki Kato has served as a consultant for Sumitomo Pharma Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Lundbeck Japan K.K., and Takeda Pharmaceutical Co., Ltd.; received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Shionogi & Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Lundbeck Japan K.K., Viatris Inc., Eisai Co., Ltd., Kyowa Pharmaceutical Industry Co., Ltd., and Ono Pharmaceutical Co., Ltd. Michael E. Thase has served as an advisor\/consultant for AbbVie (Allergan), Acadia, Alkermes, Axsome, Clexio, H. Lundbeck A\/S, Johnson & Johnson (Janssen), Merck & Company Inc., Novartis, Otsuka, Pfizer, Sage Pharmaceuticals, Sunovion Pharmaceuticals Inc., and Takeda; received grant support from Acadia, Axsome, Clexio, Janssen, National Institute of Mental Health, Otsuka, Patient-Centered Outcomes Research Institute (PCORI), and Takeda; and royalties from American Psychiatric Foundation, Guilford Publications, Herald House, Wolters Kluwer, and WW Norton & Company Inc.; and his spouse is employed by Peloton Advantage, which does business with most major pharmaceutical companies. Matthieu Boucher is an full-time employee of Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada. Francois Therrien was a full-time employee of Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada at the time of the submission and resubmission of this manuscript. A. Marilise Marrache is a full-time employee of Lundbeck Canada Inc., Saint-Laurent, Quebec, Canada. Kenta Ikehara is a full-time employee of Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan. Ferhat Ardic is a full-time employee of H. Lundbeck A\/S, Valby, Denmark.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable \u2013 manuscript has no associated data.","order":3,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors met the ICMJE criteria and all those who fulfilled these criteria are listed as authors. All authors contributed to the conceptualisation and refining of the scope of the review, analysis and interpretation of the literature, and critically reviewed the manuscript for intellectual content. All authors have read and approved the final manuscript and accept accountabilities for all aspects of the work including accuracy and integrity.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}